Payment overview · 2025
General Payments
$406.44
21 reported records · 12 companies
Healthcare provider profile · identity verified
Edward L Sames, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHELBYVILLE, KY · NPI 1508855123
Verified facts
What the public records show
CMS Open Payments records show Edward L Sames, MD received $406.44 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.24 | 16.8% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.34 | 16.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.76 | 10.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.96 | 9.6% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $33.91 | 8.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.27 | 8.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.69 | 6.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.57 | 6.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.56 | 4.6% | 1 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $18.42 | 4.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.95 | 4.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.77 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.44 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.34 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.76 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.35 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.89 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.89 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.69 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
148 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 585 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 336 | 91 |
| Lisinopril | Lisinopril | 312 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 81 |
| Losartan Potassium | Losartan Potassium | 268 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 55 |
| Metformin Hcl Er | Metformin Hcl | 253 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 51 |
| Omeprazole | Omeprazole | 216 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 45 |
| Gabapentin | Gabapentin | 163 | 46 |
| Eliquis | Apixaban | 148 | 25 |
| Simvastatin | Simvastatin | 147 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 53 |
| Montelukast Sodium | Montelukast Sodium | 140 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 36 |
| Metformin Hcl | Metformin Hcl | 137 | 33 |
| Lorazepam | Lorazepam | 131 | 21 |
| Carvedilol | Carvedilol | 129 | 25 |
| Potassium Chloride | Potassium Chloride | 126 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 27 |
| Allopurinol | Allopurinol | 114 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 23 |
| Tramadol Hcl | Tramadol Hcl | 107 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 23 |
| Alprazolam | Alprazolam | 98 | 14 |
| Meloxicam | Meloxicam | 94 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 40 |
| Sertraline Hcl | Sertraline Hcl | 83 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 20 |
| Ozempic | Semaglutide | 63 | suppressed |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 19 |
| Furosemide | Furosemide | 60 | 16 |
| Ezetimibe | Ezetimibe | 59 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | 18 |
| Trazodone Hcl | Trazodone Hcl | 55 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Spironolactone | Spironolactone | 51 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 17 |
| Torsemide | Torsemide | 47 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Famotidine | Famotidine | 44 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | 12 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 14 |
| Ramipril | Ramipril | 38 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Prednisone | Prednisone | 29 | 21 |
| Primidone | Primidone | 29 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 20 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 14 |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Valsartan | Valsartan | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Amoxapine | Amoxapine | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.44 · 21 records | Novo Nordisk Inc | ABRYSVO, CAPLYTA, COMIRNATY, CYCLOSET, Cologuard Collection Kit, FREESTYLE LIBRE 3, Korlym, MINIMED 780G, Ozempic, PREVNAR 20, Rybelsus, TRINTELLIX, VOQUEZNA, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error